今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

中软国际股价午后飙升逾5% 机构预计公司将受益于鸿蒙生态发展

北京 - 中软国际（00354）股价今日午后强势拉升，涨幅超过5%，收报4.42港元，成交额9751.34万港元。市场人士认为，中软国际的股价上涨主要受两大利好因素影响：

• 鸿蒙生态发展势头强劲。作为华为鸿蒙生态的重要合作伙伴，中软国际深度参与了鸿蒙系统的研发与推广，并已为多款鸿蒙智能终端提供软件解决方案。随着鸿蒙生态的快速发展，中软国际有望迎来新的业务增长机会。
• 公司基本面稳健。中软国际是一家领先的软件与信息技术服务企业，在金融、电信、政府等多个行业拥有丰富的经验和客户资源。公司近年来业绩稳健增长，盈利能力持续增强。

东北证券在近期发布的一份研究报告中表示，中软国际是受益于鸿蒙生态发展的主要标的之一。报告指出，公司在鸿蒙生态中的领先地位和稳健的基本面，将为其未来的发展提供强劲动力。

华泰证券则表示，中软国际的股价上涨反映了市场对公司未来发展前景的看好。随着鸿蒙生态的不断完善和渗透率提升，中软国际有望迎来更加广阔的市场空间。

机构预计中软国际将进入快速扩张期。随着鸿蒙生态的快速发展，中软国际有望在多个领域获得新的业务增长机会，包括：

• 鸿蒙操作系统开发：中软国际将继续参与鸿蒙系统的研发与推广，为华为和其他鸿蒙终端厂商提供软件解决方案。
• 鸿蒙应用开发：中软国际将积极开发鸿蒙生态下的各类应用，满足用户多样化的需求。
• 鸿蒙云服务：中软国际将提供基于鸿蒙生态的云服务，助力企业数字化转型。

总体而言，中软国际的股价上涨具有良好的基本面支撑。随着鸿蒙生态的不断发展，中软国际有望迎来更加广阔的市场空间和更高的业绩增长。